Cogent Biosciences Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Cogent Biosciences Inc.
- Former names
- Unum Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Waltham
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- COGT
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001622229
- EIN
- 46-5308248
Board of directors
-
Andrew R. Robbins · Director · President and CEOSince 2023
-
Arlene Morris · DirectorSince 2023
-
Christopher W. Cain · DirectorSince 2023
-
Karen Jean Ferrante · DirectorSince 2023
-
Matthew Ros · DirectorSince 2023
- Since 2023
-
Todd Shegog · DirectorSince 2023
Chief executives
Andrew R. Robbins
· President and CEO
Dates unknown
Director election results
Annual meeting of June 9, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
83.9%
-
86.7%
-
86.9%
Board connections
4 of this board's directors also sit on 12 other boards.
- via Arlene Morris, Christopher W. Cain and Peter Evan Harwin
- via Christopher W. Cain and Peter Evan Harwin
- via Christopher W. Cain and Peter Evan Harwin
- via Peter Evan Harwin
- via Peter Evan Harwin
- via Arlene Morris
- via Peter Evan Harwin
- via Karen Jean Ferrante
- via Peter Evan Harwin
- via Arlene Morris
- via Peter Evan Harwin
- via Peter Evan Harwin
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $383,888,198
- 8 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 27, 2026 | Arlene Morris Director | Option exercise | +41,927 | $5.64 | $236,468 |
| Aug 27, 2026 | Arlene Morris Director | Option exercise | +3,583 | $2.52 | $9,029 |
| Aug 27, 2026 | Arlene Morris Director | Open-market sale | −42,349 | $37.09 | $1,570,830 |
| Aug 27, 2026 | Arlene Morris Director | Open-market sale | −3,161 | $37.54 | $118,663 |
| May 19, 2026 | Andrew R. Robbins Director, Officer (President and CEO) | Gift | −160,000 | — | — |
| May 19, 2026 | Andrew R. Robbins Director, Officer (President and CEO) | Gift | +160,000 | — | — |
| Mar 31, 2026 | Fairmount Funds Management LLC Director | Derivative conversion | +7,000,000 | — | — |
| Mar 31, 2026 | Fairmount Funds Management LLC Director | Open-market sale | −7,000,000 | $34.66 | $242,620,000 |
| Jan 22, 2026 | Fairmount Funds Management LLC Director | Open-market sale | −3,500,000 | $36.40 | $127,400,000 |
| Dec 26, 2025 | Kearns Evan Officer (Chief Legal Officer) | Open-market sale | −65,000 | $38.70 | $2,515,500 |
| Dec 26, 2025 | Green John L. Officer (Chief Financial Officer) | Open-market sale | −77,000 | $38.68 | $2,978,360 |
| Dec 26, 2025 | Sachs Jessica Officer (Chief Medical Officer) | Open-market sale | −82,642 | $38.70 | $3,198,245 |
| Dec 26, 2025 | Robinson John Edward Officer (Chief Scientific Officer) | Open-market sale | −90,000 | $38.74 | $3,486,600 |
| Dec 17, 2025 | Robinson John Edward Officer (Chief Scientific Officer) | Grant or award | +50,000 | — | — |
| Dec 17, 2025 | Andrew R. Robbins Director, Officer (President and CEO) | Grant or award | +185,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.